Related Experiment Video
Updated: Jul 29, 2025
06:12
HUVEC Tube-formation Assay to Evaluate the Impact of Natural Products on Angiogenesis
Published on: June 24, 2019
17.0K
EZH2 can be used as a therapeutic agent for inhibiting endothelial dysfunction
Li Sun1, Xuefang Li1, Hui Luo1
1Cardiovascular Research Center, The First Affiliated Hospital of Xinxiang Medical University, Xinxiang, Henan 453100, China; Key Laboratory of Cardiovascular Injury and Repair Medicine of Henan, Weihui, China.
Biochemical Pharmacology
|May 19, 2023
Summary
Enhancer of zeste homolog 2 (EZH2) is crucial for maintaining healthy endothelial cells by regulating gene expression. This review summarizes EZH2
Area of Science:
- Molecular Biology
- Epigenetics
- Cell Biology
Background:
- Enhancer of zeste homolog 2 (EZH2) is the catalytic subunit of polycomb repressor complex 2.
- EZH2 methylates histone H3 at lysine 27, leading to gene repression via chromatin compaction.
- EZH2 plays a vital role in endothelial cell homeostasis and function.
Purpose of the Study:
- To summarize the multifaceted roles of EZH2 in endothelial cell functions.
- To explore the therapeutic potential of targeting EZH2 in cardiovascular diseases.
Main Methods:
- Literature review of studies investigating EZH2 in endothelial biology.
- Analysis of EZH2's regulatory mechanisms in endothelial functions.
- Evaluation of EZH2's involvement in cardiovascular disease pathogenesis.
Main Results:
- EZH2 regulates key endothelial processes including angiogenesis, barrier integrity, and inflammatory signaling.
- EZH2 mediates endothelial mesenchymal transition in response to environmental stimuli.
- Dysregulation of EZH2 is implicated in various cardiovascular conditions.
Conclusions:
- EZH2 is a critical regulator of endothelial cell function with significant implications for cardiovascular health.
- Targeting EZH2 presents a promising therapeutic strategy for cardiovascular diseases.
Keywords:
AngiogenesisEZH2Endothelial barrierEndothelial cellsEndothelial mesenchymal transitionInflammatory signalingMore Related Videos
Related Concept Videos
01:18Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists
205
Endothelins (ETs) are potent vasoactive peptides critical in the human body's various physiological and pathological processes. One of the most promising therapeutic strategies for treating pulmonary arterial hypertension (PAH) involves counteracting the effects of these endothelins using a class of drugs known as endothelin receptor antagonists.
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme...
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme...
205
01:30Heart Failure V: Medical Management
16
Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
16
01:24Regulation of Angiogenesis and Blood Supply
2.6K
Rapidly dividing tumors, embryos, and wounded tissues require more oxygen than usual, lowering the oxygen concentration in the blood. At low oxygen or hypoxic conditions, an oxygen-sensitive transcription factor called the hypoxia-inducible factor 1 or HIF1 is activated. HIF1 is a dimeric protein of alpha (ɑ) and beta (β) subunits. Under optimal oxygen conditions, HIF1β is present in the nucleus while HIF1ɑ remains in the cytosol. HIF1ɑ is hydroxylated by prolyl...
2.6K
01:28Treatment for Pulmonary Arterial Hypertension: Phosphodiesterase Inhibitors
200
Phosphodiesterase 5 (PDE5) inhibitors are potent enzymes that function to hydrolyze cyclic nucleotides to their corresponding 5' monophosphates. Their unique biochemical properties have been applied in treating Pulmonary Arterial Hypertension (PAH).
Among the PDE5 inhibitors, sildenafil (Revatio) stands out as a competitive and selective inhibitor. It operates by elevating cellular levels of cGMP and augmenting signaling through the cGMP-PKG pathway, promoting vasodilation. Upon oral...
Among the PDE5 inhibitors, sildenafil (Revatio) stands out as a competitive and selective inhibitor. It operates by elevating cellular levels of cGMP and augmenting signaling through the cGMP-PKG pathway, promoting vasodilation. Upon oral...
200
01:26Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
472
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
472
01:23Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists
226
Prostacyclin receptor agonists are a class of therapeutic agents integral to managing pulmonary arterial hypertension (PAH). These drugs operate by mimicking the action of prostaglandin I2, or PGI2, a naturally occurring compound in the body.
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
226